Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ore Pharmaceuticals Inc.

www.orepharma.com

Latest From Ore Pharmaceuticals Inc.

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Mark Gabrielson named CEO of Ore Pharmaceuticals

The US commercial drug development company Ore Pharmaceuticals has named Mark Gabrielson president and chief executive officer. He succeeds Charles Dimmler. Mr Gabrielson serves on the company's board of directors and was most recently managing general partner of the financial services firm p-Value Capital.

Companies

Market Insight - Drug repositioning: a new strategy for success

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment required to bring a product to market. Previously exclusive to pharmaceutical companies working to expand the applications of their marketed drugs, repositioning (also known as repurposing, reprofiling, therapeutic switching, or developing 'second use' indications) has emerged as an industry in its own right, encompassing both technology and drug companies. Today, companies involved in repositioning are charging for their services, establishing collaborative agreements and using the strategy to develop their own pipelines.

Gastrointestinal Metabolic Disorders

SimuGen Ltd.

SimuGen has developed an analysis system that includes a pre-packaged kit that customers can use to test their own compounds. Accompanying client management software then imports the data and sends it to SimuGen's servers for analysis. It produces a dose-response curve for every clinically significant toxicity and also ranks related compounds based on their toxicity profile, allowing medicinal chemists to evaluate potential leads. Finally, clustering analysis reveals how changes to the molecular structure could affect the toxicity profile. The product has been designed to work with relatively few biomarker genes, which simplifies the laboratory procedure and avoids platforms such as microarrays.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
      • Genomics-Proteomics
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Gene Logic Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ore Pharmaceuticals Inc.
  • Senior Management
  • Mark J Gabrielson, CEO & CFO
    Stephen R Donahue, MD, SVP, Clinical Dev.
    Joanne M Smith-Farrell, PhD, VP, Corp. Dev. & Strategy
  • Contact Info
  • Ore Pharmaceuticals Inc.
    Phone: (301) 987-1700
    50 W. Watkins Mill Rd.
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register